NEWS

★IR：カテゴリメニュー

タブV2

All
IR Library
Topics

2024/03/25

IR Library

Announcement of revisions to FY2023 financial guidance [PDF：78KB]
2024/03/18

IR Library

Announcement of the loan arrangement from Japan Finance Corporation [PDF：74KB]
2024/03/11

IR Library

Announcement of manufacturing of SHED Master Cell Bank in compliance with US FDA Standards [PDF：98KB]
2024/03/08

IR Library

Notice of the Nomination of Candidates for Board Directors and Corporate Auditors [PDF：105KB]
2024/02/27

お知らせIR Library

3Q FY2023 update from OMEGA Investment [PDF：695KB]
2024/02/07

IR Library

[Presentation] Financial Results for 3Q FY 2023 [PDF：922KB]
2024/02/07

IR Library

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2024
[PDF：363KB]
2024/01/12

IR Library

Announcement of establishment of a subsidiary in the cell therapy business (regenerative medicine) through a company split (simplified incorporation-type company split) [PDF：230KB]
2023/12/21

IR Library

Announcement of the bank loan arrangement from Mizuho Bank, Ltd. for increased orders of GBS-007 [PDF：147KB]
2023/11/21

IR Library

Announcement of the launch of Pegfilgrastim biosimilar [PDF：149KB]
2023/11/14

IR Library

2Q FY2023 update from OMEGA Investment [PDF：759KB]
2023/11/13

IR Library

Announcement of research results at the 43^rd Annual Scientific Meeting of the Japanese Society of Ocular Pharmacology -Optic neuroprotective effect with SHED- [PDF：126KB]
2023/11/08

IR Library

Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2024 [PDF：255KB]
2023/11/08

IR Library

[Presentation] Financial Results for 2Q FY 2023 [PDF：1089KB]
2023/10/16

IR Library

Announcement of enrollment of the first case of clinical research plan for children with cerebral palsy under the initiative of Nagoya University [PDF：142KB]
2023/09/27

IR Library

Announcement of approval of additional indication of Ranibizumab BS [PDF：141KB]
2023/09/25

IR Library

Announcement of Receiving Manufacturing and Sales Approval for biosimilar in the Oncology in Japan [PDF：204KB]
2023/08/15

IR Library

1Q FY2023 update from OMEGA Investment[PDF：982KB]
2023/08/07

IR Library

Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2024[PDF：339KB]
2023/08/07

IR Library

[Presentation] Financial Results for 1Q FY 2023[PDF：1360KB]
2023/07/14

IR Library

Correction of the press release on July 10, 2023 [PDF：187KB]
2023/07/10

IR Library

Working Capital Financing for stable supply for GBS-007 (18th series of stock acquisition rights with exercise price adjustment clause) [PDF：206KB]
2023/07/10

IR Library

[Presentation] Working Capital Financing for Stable Supply of GBS-007 [PDF：686KB]
2023/06/29

IR Library

Appointment of new CEO [PDF：156KB]
2023/06/06

IR Library

Announcement of organizational and personnel changes [PDF：196KB]
2023/06/06

IR Library

Announcement of partial changes in the Articles of Incorporation [PDF：143KB]
2023/06/06

IR Library

Announcement of appointment of New CEO and Board Directors [PDF：249KB]
2023/05/22

IR Library

Establishment of stable storage and transportation system of SHED [PDF：192KB]
2023/05/19

IR Library

Company note 4QFY2022 update from OMEGA Investment [PDF：1155KB]
2023/05/12

IR Library

[Presentation] Financial Results for the FY 2022 [PDF：1817KB]
2023/05/12

IR Library

Summary of Financial Results for the Fiscal Year Ended March 31, 2023 (Non-consolidated) [PDF：374KB]
2023/05/08

IR Library

Announcement of presentation on basic research results of SHED at American Society of Gene & Cell Therapy (ASGCT)[PDF：143KB]
2023/02/20

IR Library

The Company’s opinion on Glass Lewis’ voting recommendation on the agenda item to be proposed at the extraordinary general meeting of shareholders [PDF：152KB]
2023/02/20

IR Library

Update of clinical research plan of Nagoya University [PDF：144KB]
2023/02/13

IR Library

Company note 3Q FY2023/3 update from OMEGA Investment [PDF：800KB]
2023/02/10

IR Library

Update from Heartseed Inc.: Successful transplantation of the first case in the Phase I/II LAPiS study of HS-001, a myocardial regenerative therapy utilizing iPS cells [PDF：117KB]
2023/02/07

IR Library

[Presentation] Financial Results for the Third Quarter of FY2022 [PDF：1790KB]
2023/02/07

IR Library

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2023
(Excerpt from Japanese version) [PDF：465KB]
2023/01/30

IR Library

Update of clinical research plan of Nagoya University [PDF：144KB]
2023/01/26

IR Library

ANALYST NET Company Report was released by Fair Research Inc. [PDF：1372KB]
2023/01/13

IR Library

The Company’s opinion on shareholders’ proposal (Excerpt from Japanese version)
[PDF：191KB]
2023/01/13

IR Library

Announcement of approval of additional indication of Ranibizumab BS (Excerpt from Japanese version) [PDF：206KB]
2023/01/10

IR Library

Announcement of a patent grant for anti-RAMP2 antibodies which inhibit the formation of new blood vessels with a new mechanism [PDF：148KB]
2023/01/10

IR Library

[Presentation] Patent grant for anti-RAMP2 antibodies [PDF：1164KB]
2022/12/19

IR Library

Company Research and Analysis Report from OMEGA Investment (updated version) [PDF：2109KB]
2022/12/09

IR Library

Announcement of the record date for the convocation of extraordinary meeting of shareholders [PDF：84KB]
2022/12/07

IR Library

Announcement of research results at the annual meeting of 66th Japan Society for Neonatal Health and Development -Therapeutic effects of SHED on chronic cerebral palsy model- [PDF：257KB]
2022/12/06

IR Library

Announcement of request for convocation of extraordinary meeting of shareholders [PDF：145KB]
2022/12/05

IR Library

Announcement of participation in the open innovation initiative “i2.JP (Innovation Infusion Japan)” led by AstraZeneca K.K. [PDF：236KB]
2022/11/28

IR Library

Announcement of publication of the third research article in collaboration with Hamamatsu University School of Medicine
[PDF：151KB]

2021/01/22

Our mid-term strategic plan will be announced on Feb. 15.

We are delighted to inform you that our mid-term strategic plan will be announced on our website on Feb. 15, 2021.

Back

2019/11/22

topics

Announcement on Series B Funding by Heartseed Inc.
2019/05/10

topics

Notice of Relocation of Head Office Function, Relocation of Tokyo Office, and Integration of Subsidiaries office [PDF：137KB]
2019/05/10

topics

Announcement of signing a joint research and development agreement with ORTHOREBIRTH for cleft lip/cleft palate [PDF：198KB]
2019/03/12

topics

Notice of Resolutions at the Extraordinary General Shareholders Meeting [PDF：297KB]
2019/02/28

topics

Completion of the enrollment of the final patient in the Phase III study for ophthalmologic biosimilar [PDF：78KB]
2019/02/05

topics

FY2018 3Q IR Meeting Information [PDF：2408KB]
2019/01/31

topics

GTS and Senju sign a licensing agreement with Ocumension Therapeutics on biosimilar in ophthalmologic field [PDF：93KB]
2019/01/17

topics

[Presentation] Execution of Share Exchange Agreement and Conversion of Advanced Cell Technology and Engineering into Wholly-Owned Subsidiary of Kidswell Bio Corporation [PDF：1833KB]
2019/01/17

topics

[Announcement] Execution of Share Exchange Agreement and Conversion of Advanced Cell Technology and Engineering into Wholly-Owned Subsidiary of Kidswell Bio Corporation [PDF：348KB]
2018/09/28

topics

Submission of New Drug Application in Japan of Darbepoetin alfa Biosimilar [PDF：169KB]

Our Goal

Business

Features / Strength

Pipeline

Company Profile

IR Information

NEWS

Our mid-term strategic plan will be announced on Feb. 15.